

A multicentre phase III open-label randomized study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with rituximab after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy

Dear Investigators,

The next step of our study will be the

**9th International Conference on Malignant Lymphoma,  
in Lugano, Switzerland**

**A Prima Investigator Meeting will take place on  
Wednesday, June 08, 2005.**

**Sala delle Palme, Castalogna Hotel : 19h - 21h**

**AGENDA**


- Overview of the Protocol
- Country Status
- Inclusion Status
- Discussion
- Lunch

We look forward for your participation to this meeting,


Gilles Salles

Delphine Germain & Stephanie Baulu

**Country Status**



### Global World Recruitment - PRIMA Study



*Please note that:*

*R-CVP regimen contains **40 mg/m<sup>2</sup>** of prednisone and R-CHOP **100 mg total dose** of prednisone, each for 5 consecutive days*